Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics NASDAQ: KPTI said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance.